key: cord-0909124-077o1cmx
authors: Gronowski, Ann M; Farnsworth, Christopher W
title: In Reply: Correctly Interpreting SARS-CoV-2 Serologic Assays
date: 2020-07-17
journal: Clin Chem
DOI: 10.1093/clinchem/hvaa166
sha: 74407ab0386f91cf7528ff75f3b140a9491653ba
doc_id: 909124
cord_uid: 077o1cmx

nan

We agree with Dr. Naides that differences between sensitivity and specificity in our study (1) were statistically insignificant given overlapping confidence intervals, a point we concede in the manuscript. However, this does not imply that there are not differences between the assays.

Proportionally, we observed more false positive results (p = 0.015, chi squared test) by the EUROIMMUN than the Abbott assay. Furthermore, combining our results (1) with a similar comparison (2) demonstrates a combined, lower specificity without overlapping confidence intervals for the EUROIMMUN assay relative to the Abbott assay ( Table 1 ). In contrast, combined sensitivity was non-significantly higher for the Abbott assay relative to the EUROIMMUN assay past d14 of symptomatology. We continue to encourage submission of studies comparing commercial serological SARS-CoV-2 assays to the published literature. Nonetheless, this does imply that the EUROIMMUN assay may be less suitable than the Abbott assay for seroprevalence studies in low prevalence populations.

Dr. Naides raises an interesting point regarding our use of pandemic era specimens for specificity studies. It is conceivable for COVID-19 patients to be PCR negative but positive by immunoassay.

There was one such patient in our study who was negative by PCR but positive by three immunoassays and a separate analysis was performed and reported with this patient excluded.

However, all other specimens with results that were deemed false positive by the EUROIMMUN assay were negative by both the Abbott and Roche SARS-CoV-2 immunoassays (and PCR negative). Consistent with the orthogonal approach suggested by the CDC (3), this would be deemed a false positive result by the EUROIMMUN. Furthermore, chart review was performed on PCR negative patients with positive serological results; all but one of which (discussed above) were clinically adjudicated as non-COVID-19 patients. To our knowledge, there are no guidelines or expert consensus that state that specimens obtained from PCR negative patients acquired during the pandemic are problematic, despite Dr. Naides' claim that "most of the field" agrees with his conclusion. It is also important to note the limitations of using pre-pandemic specimens for specificity studies. These specimens are frequently taken from younger, healthier populations (generally for reference interval studies) that may have limited exposure to other coronaviruses, are less likely to have rheumatologic diseases, and frequently do not reflect the current prevalence of other diseases. For example, specimens obtained in the summer are considerably less likely to be from patients with other, acute respiratory infections. This is highlighted by a cross-reactivity panel revealing more positives (3.8%) relative to healthy donors (1.0%) on the EUROIMMUN assay (2). While these limitations and shortcomings do not preclude the use of pre-pandemic specimens as adequate controls, there are limitations with both approaches that should be noted.

We agree with Dr. Naides' conclusion that higher antibody titers and therefore higher sensitivity is likely >d21 after symptomatology. However, our validation was intentionally designed to capture the patient population we anticipate will be tested for the presence of SARS-CoV-2 antibodies at our hospital. The Infectious Diseases Society of America recommends serological SARS-CoV-2 testing for patients with acute infections that are PCR negative (4) . To this end, it is unlikely that COVID-19 patients will present after d21 of symptoms, and more unlikely that a patient with this presentation would be PCR negative. This has been consistent with our experience with inpatient populations at our institution. Furthermore, this is consistent with how other studies in the published literature (1) and other manufacturers (i.e., Abbott) have designed their validations.

Since publication of our manuscript, evidence has mounted that subdomains of the spike protein are the target of neutralizing antibodies and two comparisons between the EUROIMMUN assay and neutralizing titers have emerged in preprints. Klein et al. demonstrated a negative percent agreement (NPA) of 32% between the EUROIMMUN assay and neutralizing antibody titers > 1:360, the original titer suggested by the FDA for convalescent plasma (5) . We recently observed an NPA of 55% at a neutralizing titer of 1:128, and 35% at a neutralizing titer of 1:256 (6). Furthermore, we found similar correlation, concordance, and NPA between commercial assays that target the spike protein (EUROIMMUN) and the nucleocapsid protein (Abbott, Roche). This implies that commercial assays may have comparable utility for identifying the presence of neutralizing antibodies and convalescent plasma donors. Nonetheless, further studies in the peerreviewed literature are required to conclusively demonstrate this finding, particularly in convalescent plasma from mildly symptomatic and asymptomatic populations.

In conclusion, we stand by the results and conclusions represented in our previous manuscript. Our study accurately reflects the specimens received at our institution for SARS-CoV-2 serological testing on in-patient populations including the current burden of other diseases, acuity of patients tested, age, gender, and race. Fisher's exact test for proportional differences between the assays c One patient was excluded from the analysis that was adjudicated clinically with COVID-19 and was positive by three immunoassays despite negative molecular testing.

Clinical performance of two SARS-CoV-2 serologic assays

Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies Against SARS-CoV-2

Interim guidelines for COVID-19 antibody testing

Infectious Diseases Society of America. IDSA COVID-19 antibody primer

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Association between neutralizing antibodies to SARS-CoV-2 and commercial serological assays